BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 32910980)

  • 1. Evaluation of Abbott anti-SARS-CoV-2 CMIA IgG and Euroimmun ELISA IgG/IgA assays in a clinical lab.
    Manalac J; Yee J; Calayag K; Nguyen L; Patel PM; Zhou D; Shi RZ
    Clin Chim Acta; 2020 Nov; 510():687-690. PubMed ID: 32910980
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of the EUROIMMUN Anti-SARS-CoV-2 ELISA Assay for detection of IgA and IgG antibodies.
    Beavis KG; Matushek SM; Abeleda APF; Bethel C; Hunt C; Gillen S; Moran A; Tesic V
    J Clin Virol; 2020 Aug; 129():104468. PubMed ID: 32485620
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Performance of six SARS-CoV-2 immunoassays in comparison with microneutralisation.
    Jääskeläinen AJ; Kuivanen S; Kekäläinen E; Ahava MJ; Loginov R; Kallio-Kokko H; Vapalahti O; Jarva H; Kurkela S; Lappalainen M
    J Clin Virol; 2020 Aug; 129():104512. PubMed ID: 32563180
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assessment of SARS-CoV-2 serological tests for the diagnosis of COVID-19 through the evaluation of three immunoassays: Two automated immunoassays (Euroimmun and Abbott) and one rapid lateral flow immunoassay (NG Biotech).
    Nicol T; Lefeuvre C; Serri O; Pivert A; Joubaud F; Dubée V; Kouatchet A; Ducancelle A; Lunel-Fabiani F; Le Guillou-Guillemette H
    J Clin Virol; 2020 Aug; 129():104511. PubMed ID: 32593133
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of two automated and three rapid lateral flow immunoassays for the detection of anti-SARS-CoV-2 antibodies.
    Montesinos I; Gruson D; Kabamba B; Dahma H; Van den Wijngaert S; Reza S; Carbone V; Vandenberg O; Gulbis B; Wolff F; Rodriguez-Villalobos H
    J Clin Virol; 2020 Jul; 128():104413. PubMed ID: 32403010
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serological Evaluation of Human Antibodies of the Immunoglobulin Class A and G Against SARS-CoV-2 in Serum Collected in Newfoundland and Labrador.
    Needle R; Gilbert L; Zahariadis G; Yu Y; Dalton-Kenny H; Russell RS; Wang P; Donovan C; Hookey S; Jiao L
    Viral Immunol; 2021 Apr; 34(3):182-189. PubMed ID: 33739895
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Performance of the EUROIMMUN Anti-SARS-CoV-2 ELISA Assay for detection of IgA and IgG antibodies in South Africa.
    Gededzha MP; Mampeule N; Jugwanth S; Zwane N; David A; Burgers WA; Blackburn JM; Grove JS; George JA; Sanne I; Scott L; Stevens W; Mayne ES
    PLoS One; 2021; 16(6):e0252317. PubMed ID: 34161348
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Validation of a commercially available SARS-CoV-2 serological immunoassay.
    Meyer B; Torriani G; Yerly S; Mazza L; Calame A; Arm-Vernez I; Zimmer G; Agoritsas T; Stirnemann J; Spechbach H; Guessous I; Stringhini S; Pugin J; Roux-Lombard P; Fontao L; Siegrist CA; Eckerle I; Vuilleumier N; Kaiser L;
    Clin Microbiol Infect; 2020 Oct; 26(10):1386-1394. PubMed ID: 32603801
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Performance Characteristics of Four High-Throughput Immunoassays for Detection of IgG Antibodies against SARS-CoV-2.
    Theel ES; Harring J; Hilgart H; Granger D
    J Clin Microbiol; 2020 Jul; 58(8):. PubMed ID: 32513859
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Performance evaluation of Abbott ARCHITECT SARS-CoV-2 IgG immunoassay in comparison with indirect immunofluorescence and virus microneutralization test.
    Meschi S; Colavita F; Bordi L; Matusali G; Lapa D; Amendola A; Vairo F; Ippolito G; Capobianchi MR; Castilletti C;
    J Clin Virol; 2020 Aug; 129():104539. PubMed ID: 32679298
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Assessment of commercial SARS-CoV-2 antibody assays, Jamaica.
    Butterfield TR; Bruce-Mowatt A; Phillips YZR; Brown N; Francis K; Brown J; Walker JP; McKnight NAL; Ehikhametalor K; Taylor DK; Bruce CA; McGrowder D; Wharfe G; Sandiford SL; Thompson TK; Anzinger JJ
    Int J Infect Dis; 2021 Apr; 105():333-336. PubMed ID: 33610776
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Performance of an automated chemiluminescence SARS-CoV-2 IG-G assay.
    Lau CS; Oh HML; Hoo SP; Liang YL; Phua SK; Aw TC
    Clin Chim Acta; 2020 Nov; 510():760-766. PubMed ID: 32910979
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of the performance of SARS-CoV-2 serological tools and their positioning in COVID-19 diagnostic strategies.
    Velay A; Gallais F; Benotmane I; Wendling MJ; Danion F; Collange O; De Sèze J; Schmidt-Mutter C; Schneider F; Bilbault P; Meziani F; Fafi-Kremer S
    Diagn Microbiol Infect Dis; 2020 Dec; 98(4):115181. PubMed ID: 32957073
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of four new commercial serologic assays for determination of SARS-CoV-2 IgG.
    Krüttgen A; Cornelissen CG; Dreher M; Hornef M; Imöhl M; Kleines M
    J Clin Virol; 2020 Jul; 128():104394. PubMed ID: 32416599
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Testing for COVID-19: a few points to remember.
    Krátká Z; Luxová Š; Malíčková K; Fürst T; Šimková H
    Cas Lek Cesk; 2020; 159(2):72-77. PubMed ID: 32434339
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multi-Platform Comparison of SARS-CoV-2 Serology Assays for the Detection of COVID-19.
    Suhandynata RT; Hoffman MA; Kelner MJ; McLawhon RW; Reed SL; Fitzgerald RL
    J Appl Lab Med; 2020 Nov; 5(6):1324-1336. PubMed ID: 32766840
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of 3 SARS-CoV-2 IgG Antibody Assays and Correlation with Neutralizing Antibodies.
    Rychert J; Couturier MR; Elgort M; Lozier BK; La'ulu S; Genzen JR; Straseski JA; Delgado JC; Slev PR
    J Appl Lab Med; 2021 Apr; 6(3):614-624. PubMed ID: 33064790
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Monitoring antibody response following SARS-CoV-2 infection: diagnostic efficiency of 4 automated immunoassays.
    Wolff F; Dahma H; Duterme C; Van den Wijngaert S; Vandenberg O; Cotton F; Montesinos I
    Diagn Microbiol Infect Dis; 2020 Nov; 98(3):115140. PubMed ID: 32829098
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of commercially available immuno-magnetic agglutination in comparison to enzyme-linked immunosorbent assays for rapid point-of-care diagnostics of COVID-19.
    Moeller ME; Fock J; Pah P; Veras AC; Bade M; Donolato M; Israelsen SB; Eugen-Olsen J; Benfield T; Engsig FN
    J Med Virol; 2021 May; 93(5):3084-3091. PubMed ID: 33547818
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of commercial lateral flow immunoassays and ELISA for SARS-CoV-2 antibody detection.
    Serrano MM; Rodríguez DN; Palop NT; Arenas RO; Córdoba MM; Mochón MDO; Cardona CG
    J Clin Virol; 2020 Aug; 129():104529. PubMed ID: 32659710
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.